Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Knowbe4, Inc. (KNBE)
Zymergen Inc. (ZY)
Neuropace Inc (NPCE)
Upcoming IPO
Agiliti, Inc (AGTI)
Treace Medical Concepts, Inc. (TMCI)
Latham Group, Inc. (SWIM)
Rain Therapeutics Inc. (RAIN)
Impel Neuropharma, Inc. (IMPL)
Ftc Solar, Inc. (FTCI)
Aveanna Healthcare Holdings Inc. (AVAH)
Endeavor Group Holdings (EDR)
The Fortegra Group, Inc. (FRF)
Privia Health Group, Inc. (PRVA)
Priced IPO
Uipath Inc (PATH)
Doubleverify Holdings, Inc. (DV)
Skywater Technology, Inc. (SKYT)
Infobird (IFBD)
Troika Media Group, Inc. (TRKA)
Biomea Fusion, Inc. (BMEA)
Akoya Biosciences, Inc. (AKYA)
Recursion Pharmaceuticals, Inc. (RXRX)
Karat Packaging Inc. (KRT)
AppLovin (APP)
Esports Technologies (EBET)
Agilon Health, Inc. (AGL)
TuSimple Holdings Inc (TSP)
Coinbase Global, Inc. (COIN)
Alkami Technology, Inc. (ALKT)
Reneo Pharmaceuticals, Inc. (RPHM)
Vectivbio Holding Ag (VECT)
UTime Limited (UTME)
Frontier Group Holdings (ULCC)
Compass, Inc. (COMP)
More companies

Achilles Therapeutics Inc. (ACHL)

Sector - Healthcare

Price chart

-10.08%
Return from IPO

Company News

IPO Profile

About company

They are a clinical stage immuno-oncology biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumors. They are focused on advancing cancer therapies through their pioneering work in the field of tumor evolution and their belief that clonal neoantigens represent the most specific class of cancer cell targets. They are currently conducting two open-label Phase I/IIa trials to evaluate their cNeT product candidate, ATL001, in advanced NSCLC and metastatic or recurrent melanoma and expect to report interim data from these trials in the second half of 2022. They are also using their Material Acquisition Platform, or MAP, network, which consists of a network of participating medical facilities, to collect tissue samples from other tumor types, such as head and neck squamous cell carcinoma, or HNSCC, renal cell carcinoma, or RCC, triple negative breast cancer, or TNBC, and bladder cancer, to develop their PELEUS platform to identify clonal neoantigens in these tumor types. They expect to file investigational new drug applications, or INDs, for their earlier stage programs in the second half of 2021 and in the second half of 2023. They expect these INDs to be for their HNSCC and RCC programs, with HNSCC expected to be the lead program.
Industry
Biological Products (no Diagnostic Substances)
CEO CFO
Iraj Ali Robert Coutts
Employees Founded
153 2016

Contacts

Address: 245 Hammersmith Road London W6 8pw United Kingdom

Telephone: +44 (0)20 8154 4600

Web page: http://www.achillestx.com

IPO information

First Trade Date 3/31/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 9.75
Shares Revised (MM) 9.8
Expected offer amount (MM) $175.5
Realized offer amount(MM) $176.4

Financial Data (last reporting year)

Market Cap (MM) $731.16
Revenues (MM) $0
Net Income (Loss) (MM) $-33.2

Voting

What do you think will happen with the ACHL share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: JP Morgan

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
JP Morgan/ BofA Securities/ Piper Sandler
CO-Managers
Chardan Capital Markets/ Oppenheimer & Co./ Kempen

Sector: Healthcare

Tweets about $ACHL

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats